Omeros Financial Ratios
NASDAQ: OMERHealth CareBiotechnology: Pharmaceutical PreparationsUSD
19.83+0.71 (+3.71%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Omeros ratio analysis
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Omeros financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | — | — | 2.97 | 2.06 | — | — | — | — | — |
| Price / sales | — | — | — | — | — | 11.07 | 5.92 | 20.20 | 13.65 | 9.64 |
| Price / book | — | — | — | 1.65 | 16.86 | — | — | — | — | — |
| Gross margin | — | — | — | — | — | 98.8% | 99.2% | 98.3% | 98.3% | 96.6% |
| Operating margin | — | — | — | — | — | -212.6% | -130.6% | -375.7% | -67.7% | -130.4% |
| Net margin | — | — | — | — | — | -187.0% | -75.6% | -424.4% | -82.5% | -160.4% |
| Free cash flow margin | — | — | — | — | — | -136.0% | -54.0% | -349.2% | -56.4% | -124.1% |
| Return on equity (ROE) | — | — | — | 55.3% | 816.8% | — | — | — | — | — |
| Return on assets (ROA) | -1.0% | -56.6% | -31.1% | 8.0% | 46.3% | -76.3% | -61.7% | -132.1% | -46.0% | -99.2% |
| Debt / equity | — | — | — | 2.58 | 13.18 | — | — | — | — | — |
| Current ratio | 2.76 | 1.69 | 4.09 | 3.25 | 4.79 | 4.12 | 1.87 | 2.41 | 4.12 | 3.75 |
| Revenue growth | — | — | — | — | — | -34.0% | 274.3% | -53.9% | 55.8% | 208.1% |
| EPS growth | — | — | -347.4% | -75.6% | — | — | — | — | — | — |